NCT06581822Active, not recruiting
Biomarkers for Pharmacoresponse in Bipolar Disorder - Coagulation
Source: ClinicalTrials.gov · Last updated 19 Feb 2025
Brief summary (registry, in English)
Previous studies indicate an association between severe psychiatric disorders, such as bipolar disorder, and increased risk of venous thromboembolism. However, to which extent this association is influenced by lithium treatment is currently unknown. In this prospective cohort study, the investigators aim to investigate the effect of bipolar disorder and lithium treatment on coagulation and the counterpart fibrinolysis.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 68 (actual)
- First submitted
- 29 May 2024
- Start date
- 24 Feb 2017
- Primary completion date
- Apr 2025
- Lead sponsor
- Karolinska Institutet
- Diseases
- Bipolar disorder
- NCT number
- NCT06581822
What you commit to
- Study type: Observational
- Participants enrolled: 68
- From 24 Feb 2017 to the primary completion date, Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to give informed consent
Who the study is looking for
- Patients diagnosed with bipolar disorder but not yet treated with lithium, where there is a decision by the patient and the responsible doctor to start lithium treatment.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska Institutet Coordinator of this site? Confirm its status | Stockholm | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.